Health News
Chemo Overdose Rx Approved
The U.S. Food and Drug Administration today approved Vistogard (uridine triacetate) for the emergency treatment of adults and children who receive an overdose of the cancer treatment fluorouracil or capecitabine, or who develop certain severe or life-threatening toxicities within four days of receiving these cancer treatments.
When Chemo Fails, This Rx May Help
Breast cancer patients and their doctors may now have a new tool in their toolbox.
Bone Rx Boosted Breast Cancer Survival
Nearly all postmenopausal women with early-stage HR+ breast cancer are treated with aromatase inhibitors. But these drugs can significantly compromise bone health and up the risk of fractures.
Approved: Possible Solution to Chemotherapy Hair Loss
Women facing chemotherapy for breast cancer may face another side effect: hair loss. But a new device could fight back.
Device to Reduce Chemo Hair Loss Cleared for Marketing
Today, the U.S. Food and Drug Administration cleared for marketing in the United States the first cooling cap to reduce hair loss (alopecia) in female breast cancer patients undergoing chemotherapy.
The Best Flu Shot for High-Risk Cancer Patients
For patients with cancers of the immune system, such as multiple myeloma, common infections like the flu can be especially dangerous. And new evidence suggests that standard flu shots may not offer adequate protection for these patients.
Tamoxifen and Antidepressants: The New Findings
Breast cancer survivors are often prescribed antidepressants to ward off hot flashes and other side effects of the cancer drug tamoxifen. But some experts worry that this practice may make tamoxifen less effective.
A Glimmer of Hope for Advanced Breast Cancer
Ladies, you may have a better chance of fighting late-stage breast cancer today than ever before.
FDA OKs Lung Cancer Rx Portrazza
The U.S. Food and Drug Administration today approved Portrazza (necitumumab) in combination with two forms of chemotherapy to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) who have not previously received medication specifically for treating their advanced lung cancer.
Opdivo Approved to Treat Kidney Cancer
The U.S. Food and Drug Administration today approved Opdivo (nivolumab) to treat patients with advanced (metastatic) renal cell carcinoma, a form of kidney cancer, who have received a certain type of prior therapy.